Abstract 14714: Long-Term Neurocognitive Safety of LDL-C Lowering With Evolocumab: Open-Label Extension Data From FOURIER

医学 Evolocumab公司 安慰剂 中止 情景记忆 认知功能衰退 不利影响 随机对照试验 内科学 认知 精神科 痴呆 病理 替代医学 胆固醇 疾病 载脂蛋白A1 载脂蛋白B
作者
André Zimerman,Michelle L. O’Donoghue,Xinhui Ran,KyungAh Im,Brian F Ott,François Mach,Kenton H. Zavitz,Christopher E. Kurtz,Maria Laura Monsalvo,Bei Wang,Dan Atar,Anthony Keech,Marc S. Sabatine,Robert P. Giugliano
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:148 (Suppl_1)
标识
DOI:10.1161/circ.148.suppl_1.14714
摘要

Background: Concerns have been raised about low LDL-C levels and possible adverse effects on cognition. PCSK9 inhibitors markedly lower LDL-C, yet EBBINGHAUS, a prespecified substudy within the FOURIER trial, did not show adverse cognitive changes with evolocumab over 19 months median follow-up. Purpose: To investigate the long-term effects of evolocumab on cognitive function. Methods: EBBINGHAUS was a substudy of cognitive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB) within the FOURIER randomized trial of evolocumab vs placebo in patients with established ASCVD. Patients in North America and Europe who completed EBBINGHAUS on study drug were eligible for an open-label extension (OLE) study with evolocumab. The primary endpoint was change in spatial working memory strategy index of executive function score (SWMI) from baseline over time. Secondary endpoints were measures of working memory, episodic memory, and psychomotor speed. A paired t-test was used to compare baseline vs post-baseline scores during OLE. Results: Of 1204 patients from EBBINGHAUS, 306 entered the OLE and were treated with evolocumab for a median of 5.1 years. Median achieved LDL-C was 34 mg/dL (IQR 21-50). No significant change in SWMI occurred during the OLE period overall [mean (±SD) change -0.1±2.7, p=0.73] or when stratified by original randomized allocation ( Figure 1A ). For secondary outcomes, one showed no change during the OLE period, two showed small changes (10-15% of SD), but these were directionally inconsistent (one higher, one lower). In 152 patients originally randomized to evolocumab, there was no significant change in SWMI from randomization through long-term follow-up over a median of 6.7 and a maximum of 7.2 years (mean change 0.1±2.6, p=0.66) ( Figure 1B ). Conclusion: Evolocumab did not lead to any apparent long-term decline in cognitive function through follow-up extending up to 7.2 years.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
耳机单蹦发布了新的文献求助10
1秒前
索大学术完成签到,获得积分10
1秒前
2秒前
2秒前
轻松惜筠发布了新的文献求助10
3秒前
木笔朱瑾完成签到 ,获得积分10
3秒前
小虫完成签到,获得积分10
3秒前
高大莺发布了新的文献求助10
4秒前
DrD发布了新的文献求助10
4秒前
Yyy发布了新的文献求助10
5秒前
华仔应助英吉利25采纳,获得10
5秒前
没有昵称完成签到,获得积分10
5秒前
852应助晒太阳的加菲猫采纳,获得10
6秒前
6秒前
杜大帅完成签到,获得积分10
6秒前
Hello应助NYZ采纳,获得10
6秒前
健忘症发布了新的文献求助10
8秒前
爆米花应助wangxin采纳,获得10
8秒前
9秒前
SYLH应助少年弦采纳,获得10
10秒前
顺利毕业完成签到,获得积分10
11秒前
11秒前
晒太阳的加菲猫完成签到,获得积分10
11秒前
脑洞疼应助陈广辉采纳,获得10
12秒前
小琦琦发布了新的文献求助10
12秒前
Dasein完成签到 ,获得积分10
12秒前
pcwang完成签到,获得积分10
13秒前
羊羊羊发布了新的文献求助10
13秒前
zz完成签到,获得积分10
13秒前
轻松惜筠完成签到,获得积分20
14秒前
zz发布了新的文献求助10
14秒前
14秒前
15秒前
zzzzzzz发布了新的文献求助10
15秒前
小哥发布了新的文献求助10
15秒前
sevenvictory应助爱吃香菜采纳,获得10
16秒前
1580071102完成签到,获得积分10
16秒前
默默完成签到 ,获得积分10
17秒前
Akim应助momo采纳,获得10
17秒前
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3966615
求助须知:如何正确求助?哪些是违规求助? 3512055
关于积分的说明 11161483
捐赠科研通 3246880
什么是DOI,文献DOI怎么找? 1793552
邀请新用户注册赠送积分活动 874482
科研通“疑难数据库(出版商)”最低求助积分说明 804420